🔗 Share this article Users Stopping Anti-Obesity Injections Gain Back Weight at a Quadrupled Rate Than Dieters Weight management often requires ongoing approaches. Fresh analysis indicates that individuals who discontinue popular weight-loss injections like semaglutide or tirzepatide may regain lost weight at a significantly accelerated pace than those who end traditional diet and exercise regimens. Findings released in a prominent medical journal points out that while obese individuals frequently drop substantial amounts of their body weight while undergoing treatment, the weight returns at an average rate of 0.8 kg per month once they quit. "Individuals using such treatments need to be informed of the danger of rapid weight regain when the treatment is stopped," stated researcher Dr. Susan Jebb. That rate of recovery suggests a return to starting mass in about one and a half years. Comparing Treatments The study, which examined dozens of trials involving thousands of patients, compared the outcomes of the injectable medications with conventional dieting. The team emphasize that individuals who shed pounds through dieting generally see a slower weight regain—around 100 grams monthly—after stopping. Explaining the Rapid Regain Doctors believe the way of the jabs explains the heightened regain. These medications copy a body's own chemical called glucagon-like peptide-1, which controls feelings of fullness. "Artificially providing the hormone concentrations several times higher than the body's typical production may cause the system to generate a reduced amount of its endogenous hormone, and could lessen sensitivity to its effects," said Dr. Adam Collins, a dietetics expert. "Discontinuation of this hormone supplement leads to appetite is uncontrolled, making excessive eating far more likely." A Lifelong Condition? The NHS suggest the injections for individuals with obesity-related health risks, alongside prescribed diet and exercise modifications. A number of clinicians contend that, due to the high risk of relapse, the treatment might need to be life-long. This perspective is echoed by drug manufacturers, who note that the results "underscore the long-term nature of obesity," similar to managing diseases like high blood pressure. User Testimonies Users who have come off the medication explain a intense return of appetite. "I experienced a trigger activating and you become ravenous," recalled a patient. The struggle is compounded if individuals have not developed sustainable dietary or behavioural modifications during therapy. Significant Use Figures show that millions of people in the UK have used weight-loss jabs in the past year, with desire remaining high. Use is greater among women compared to males. The middle-aged demographic shows the highest level of interest. A large proportion access the drugs through private prescriptions rather than public health services. Ultimately, clinicians caution that while these medications are potent tools for weight loss, they are not a permanent solution and maintained weight loss hinges on integrated behavioural management.
Weight management often requires ongoing approaches. Fresh analysis indicates that individuals who discontinue popular weight-loss injections like semaglutide or tirzepatide may regain lost weight at a significantly accelerated pace than those who end traditional diet and exercise regimens. Findings released in a prominent medical journal points out that while obese individuals frequently drop substantial amounts of their body weight while undergoing treatment, the weight returns at an average rate of 0.8 kg per month once they quit. "Individuals using such treatments need to be informed of the danger of rapid weight regain when the treatment is stopped," stated researcher Dr. Susan Jebb. That rate of recovery suggests a return to starting mass in about one and a half years. Comparing Treatments The study, which examined dozens of trials involving thousands of patients, compared the outcomes of the injectable medications with conventional dieting. The team emphasize that individuals who shed pounds through dieting generally see a slower weight regain—around 100 grams monthly—after stopping. Explaining the Rapid Regain Doctors believe the way of the jabs explains the heightened regain. These medications copy a body's own chemical called glucagon-like peptide-1, which controls feelings of fullness. "Artificially providing the hormone concentrations several times higher than the body's typical production may cause the system to generate a reduced amount of its endogenous hormone, and could lessen sensitivity to its effects," said Dr. Adam Collins, a dietetics expert. "Discontinuation of this hormone supplement leads to appetite is uncontrolled, making excessive eating far more likely." A Lifelong Condition? The NHS suggest the injections for individuals with obesity-related health risks, alongside prescribed diet and exercise modifications. A number of clinicians contend that, due to the high risk of relapse, the treatment might need to be life-long. This perspective is echoed by drug manufacturers, who note that the results "underscore the long-term nature of obesity," similar to managing diseases like high blood pressure. User Testimonies Users who have come off the medication explain a intense return of appetite. "I experienced a trigger activating and you become ravenous," recalled a patient. The struggle is compounded if individuals have not developed sustainable dietary or behavioural modifications during therapy. Significant Use Figures show that millions of people in the UK have used weight-loss jabs in the past year, with desire remaining high. Use is greater among women compared to males. The middle-aged demographic shows the highest level of interest. A large proportion access the drugs through private prescriptions rather than public health services. Ultimately, clinicians caution that while these medications are potent tools for weight loss, they are not a permanent solution and maintained weight loss hinges on integrated behavioural management.